178 Holistic Product Development: A Journey From Drug Discovery to Clinical Reality

Description:
This sessions seeks contributions that link the multiple steps of development and promote the cross-discipline interactions. Holistic product developmet will enable an upstream design guiding development desicions to fullfill clinical needs.

Sponsor:
Pharmaceutical Discovery, Development and Manufacturing Forum

Chair:
Richard Schild
Email: richard.schild@bms.com

Co-chairs:
Christopher L. Burcham
Email: cburcham@lilly.com

Mary T. am Ende
Email: mary.t.am.ende@pfizer.com

Paul Collins
Email: collinspa@lilly.com


Papers:

3:15 PM
(178a) A Novel Computational Oral Absorption Simulation Tool to Integrate API Crystal Properties and Drug Product Design Attributes to in Vitro and in Vivo Performance
Kazuko Sagawa, Ravi M. Shanker, Rong Li, Kaoutar Abbou Oucherif, Dan Braido, Filipe Calado and Sean K. Bermingham

3:35 PM
(178b) Differential Diagnosis of Primary Hyperparathyroidism and Extent of Progression Through Short-Term Calcium Loading
Christopher R. Christie, Luke E. K. Achenie and Babatunde A. Ogunnaike

3:55 PM
(178c) Polymer Inhibition of Crystal Growth for Improved Drug Solubility
Caitlin Schram, Stephen Beaudoin and Lynne Taylor

4:15 PM
(178d) Experiences in the Corporate-Wide Deployment of Advanced Modeling Technology: Making the Complicated Look Simple, But No Simpler Than That!
Salvador García-Muñoz and Paul Schmitz

4:35 PM
Break

4:45 PM
(178e) Study of GW786034 Crystallization Kinetics in Pazopanib Eye Drop
Wenning Dai

5:05 PM
(178f) Quality By Design in Integrated Processes: From Drug Substance to Drug Product
Marco Gil Sr., Filipe Gaspar Sr. and Nuno Matos

5:25 PM
(178g) Concomitant Co-Crystallization On Engineered Surfaces
Xingyi Shi, Shin Yee Wong, Xiaochuan Yang and Allan S. Myerson
See more of this Group/Topical: Pharmaceutical Discovery, Development and Manufacturing Forum
<< Previous Session | Next Session >>